GORD (reflux): what works, what doesn't, when to investigate

What GORD actually is

Gastro-oesophageal reflux disease (GORD) is the result of stomach acid (and sometimes bile) refluxing into the oesophagus frequently enough or strongly enough to cause symptoms or tissue damage. About 10–20% of Australian adults experience GORD symptoms regularly, with about 5% having erosive disease visible on endoscopy.

The cardinal symptoms are familiar: heartburn (retrosternal burning), acid regurgitation, and chest discomfort that’s worse lying down or bending forward. Less obviously, GORD can present atypically in about 30% of cases — chronic cough, throat clearing, hoarseness, dental erosion, sleep disturbance, asthma worsening.

The underlying mechanism is lower oesophageal sphincter dysfunction — either transient relaxations, sustained low tone, or anatomical distortion via hiatus hernia. Contributing factors include obesity, large meals, fatty meals, alcohol, smoking, pregnancy, and certain medications.

A. Core clinical — diagnosis and management framework

When to treat empirically, when to investigate

Most adults with typical symptoms (heartburn, regurgitation), no alarm features, and age under 55 can be treated empirically without endoscopy. The AU pathway:

1. Lifestyle measures (always)
2. Trial of PPI at standard dose for 4–8 weeks
3. Reassess at the trial endpoint — symptoms control: step down. Symptoms persist: investigate or escalate.

Alarm features that change the pathway and warrant gastroscopy:

• Unintentional weight loss
• Dysphagia (difficulty swallowing) or odynophagia (painful swallowing)
• Iron-deficiency anaemia
• Melaena or haematemesis
• Persistent vomiting
• Palpable mass
• Age ≥55 with new-onset reflux symptoms (varies — some guidelines use ≥50 for men over 50 with chronic GORD)
• Family history of upper GI cancer
• Failed PPI response after 4–8 weeks

Per Therapeutic Guidelines and the Gastroenterological Society of Australia.

Lifestyle measures with AU-supported evidence

Intervention	Effect
Weight reduction in overweight	Modest to substantial symptom improvement
Elevate head of bed 15–20 cm	Reduces nocturnal reflux; pillows alone don’t work — frame elevation does
No large meal within 3 hours of bed	Reduces nocturnal symptoms
Avoid identified personal triggers	Trial-and-document approach
Reduce alcohol	Particularly evenings
Smoking cessation	Reduces LES tone problems
Avoid tight-waisted clothing	Reduces intra-abdominal pressure

Pharmacotherapy

The AU stepwise approach per Therapeutic Guidelines and AMH:

1. Antacids (Mylanta, Gaviscon) — on-demand for occasional breakthrough
2. H2-receptor antagonists (famotidine, nizatidine) — milder symptoms, on-demand or short course
3. PPI (omeprazole, esomeprazole, pantoprazole, rabeprazole, lansoprazole) — standard for confirmed/likely GORD; 4–8 week trial then reassess
4. Twice-daily PPI — for inadequate response to once-daily; consider extra-oesophageal symptoms
5. Adjuncts — alginate-based preparations (Gaviscon) for breakthrough; baclofen has occasional use in refractory cases under specialist supervision
6. Anti-reflux surgery (laparoscopic fundoplication, magnetic sphincter augmentation) — large hiatus hernia, refractory GORD, intolerance of PPI, patient preference

B. Evidence appraisal — what’s contested and what’s settled

PPIs are highly effective short-term. Symptom resolution in 80–90% of typical GORD; erosive oesophagitis healing in 80–90% at 8 weeks. This isn’t disputed.

PPI safety in long-term use. The contested area. Observational studies have raised concerns about:

• B12 and magnesium deficiency — real, modest; consider checking after >2 years of use
• Fracture risk — small increase in older adults on long-term PPI; clinically meaningful in those with osteoporosis or fall risk
• Clostridioides difficile infection — moderate signal, particularly with concurrent antibiotic use
• Community-acquired pneumonia — small signal, more in elderly
• Chronic kidney disease and dementia — contested; signals in observational data not consistently replicated in better-controlled designs

For most patients with appropriate indication, benefits outweigh risks. The AU position via Choosing Wisely Australia and NPS MedicineWise: annual review of indication; trial of deprescribing where symptoms have resolved; avoid indefinite PPI for symptoms that have not been confirmed by structured trial.

Deprescribing protocols. Direct cessation produces rebound acid hypersecretion — paradoxically worse symptoms for 2–4 weeks even in people who didn’t truly have GORD. Australian Prescriber recommends a structured taper: halve dose for 2 weeks → alternate-day for 2 weeks → on-demand only. About 50% of long-term PPI users successfully come off completely.

Refractory reflux. When standard PPI fails, the differential includes:

• Functional heartburn (visceral hypersensitivity without acid evidence)
• Eosinophilic oesophagitis (allergic/Th2 condition; biopsy at endoscopy required)
• Non-acid reflux (bile, weakly acidic)
• Hiatus hernia requiring surgical consideration
• Achalasia or other motility disorders
• Mimics — angina, gastric cancer

Specialist gastroenterology referral via GESA-directory practices is appropriate for refractory cases.

Barrett’s oesophagus. A small proportion of chronic GORD patients develop Barrett’s — metaplastic change of oesophageal lining toward intestinal-type epithelium. Annual progression to adenocarcinoma is small (~0.1–0.5%/year) but warrants surveillance. AU recommendation: once-only gastroscopy in men over 50 with chronic (>5 years) GORD, particularly with multiple risk factors (obesity, smoking).

C. Australian operations — what the visit looks like

The AU pathway uses standard general practice items:

• Standard or long consultation (items 23, 36, or 44) for new diagnosis, treatment review, deprescribing conversation
• Pathology — FBC if anaemia suspected, ferritin, B12 if on long-term PPI, H. pylori testing in specific contexts
• Gastroscopy referral when alarm features present — public or private gastroenterology
• GPCCMP for refractory or complicated GORD with comorbidity — opens allied-health visits (dietitian especially useful)
• Pharmacist medication review (HMR — Home Medicines Review, MBS item 900) — useful when patient on multiple medications including PPI

(MBS / PBS items verified 2026-05-18 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

D. Practical guidance — typical patient stories

The new presenter, typical symptoms, no alarms:

1. Long consultation, history-taking, examination
2. Lifestyle measures introduced (weight, head of bed, dinner timing, alcohol)
3. PPI trial 4–8 weeks at standard dose
4. Review — symptoms controlled: plan step-down; persistent: investigate or step up

The chronic PPI user wanting off:

1. Confirm original indication and current symptoms (some are unsure why they started)
2. Structured taper per Australian Prescriber protocol
3. Antacid for breakthrough symptoms during taper
4. Lifestyle measures reinforced
5. Endoscopy if not previously done and risk factors present

The refractory patient on twice-daily PPI:

1. Verify adherence and timing (30 min before meals)
2. Re-examine the diagnosis — alternative explanations
3. Gastroscopy with biopsies (eosinophilic oesophagitis?)
4. pH/impedance testing in specialist setting
5. Consider surgical consultation if anatomy + symptoms align

When to seek help sooner rather than later

GORD red flags warranting prompt review:

• Trouble swallowing (food sticking)
• Painful swallowing
• Unintentional weight loss
• Vomiting blood or coffee-ground material
• Black tarry stools
• Iron-deficiency anaemia found on bloods
• Chest pain — important to distinguish reflux pain from cardiac pain; if in any doubt about cardiac origin, treat as cardiac and call 000
• Persistent symptoms despite 8 weeks of PPI
• New symptoms in adults 55+

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines, the Gastroenterological Society of Australia, NPS MedicineWise, Choosing Wisely Australia — and major international gastroenterology guidance. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about PPI use, endoscopy, and treatment escalation are made with your own GP and treating clinicians.

For Australian consumer-friendly sources: HealthDirect — Reflux, Better Health Channel — Reflux.

---

Sources cited

1. RACGP
2. Therapeutic Guidelines (eTG) — Gastrointestinal
3. Gastroenterological Society of Australia (GESA)
4. Australian Medicines Handbook
5. NPS MedicineWise
6. Choosing Wisely Australia
7. Australian Prescriber
8. HealthDirect
9. Better Health Channel
10. Katz PO et al. — ACG GERD guideline (Am J Gastroenterol 2022)
11. Kahrilas PJ et al. — AGA refractory GERD update (Gastroenterology 2018)